Onego Bio’s Patent Challenge Against EVERY Dismissed in Delaware

A US federal court in Delaware has dismissed Onego Bio's lawsuit against The EVERY Company, concluding a year-long dispute over a patent related to the production of ovalbumin through precision fermentation. Onego sought a declaratory judgment that it did not infringe EVERY's patent, but the court declined to issue this judgment or rule on the validity of the patent or infringement by Onego. The court found that EVERY did not make a threat to sue Onego and described their statements as "forms of puffing rather than actual threats."

Onego Bio, a spinout of VTT Technical Research Centre of Finland, is now selling Bioalbumen egg protein to US customers. Despite the closure of US litigation, questions regarding EVERY's patent family remain with patent offices in other markets. Onego claims that patent offices in various countries have rejected or raised objections to EVERY's patent applications, and it plans to continue monitoring these proceedings while focusing on commercialization and expanding its market presence alongside EVERY in the precision-fermented egg proteins sector.